Redcare Pharmacy stock gains 4.77 percent as guidance rises
Published on 09/30/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Redcare Pharmacy (NL0012044747) stock was trading at EUR 74.75 at Lang & Schwarz on September 30, 2026 at 4:08 p.m. CEST, up 4.77 percent versus the prior close of EUR 71.35. The move followed a second upgrade to fiscal 2026 guidance, with FT.com reporting the company announcement dated September 28, 2026.
Rx revenue drives the upgrade
Redcare now expects German prescription revenue of EUR 730 million to EUR 760 million in fiscal 2026, compared with its previous range of EUR 680 million to EUR 720 million. Total revenue growth guidance also moved from 15 percent to 17 percent to 16 percent to 18 percent, while the adjusted EBITDA margin outlook stayed at 2.5 percent to 3.0 percent, according to FT.com.
Preliminary German Rx revenue grew 56 percent year over year in the third quarter and 51 percent in September. The company attributed the upgrade to continued momentum in e-prescriptions, while non-Rx growth guidance remained at 10 percent to 12 percent.
Profitability remains the test
The second-quarter figures show why revenue growth is not the only issue. Stockhouse reported that Q2 2026 group revenue rose 20 percent to EUR 853 million, while adjusted EBITDA increased 63 percent to EUR 29.60 million and the adjusted EBITDA margin expanded from 2.60 percent to 3.50 percent.
The same report noted that gross margin declined from 23.80 percent to 22.10 percent as prescription products took a larger share of sales. That contrast gives the guidance update its central investment question: whether fast German Rx growth can scale without diluting profitability.
Jefferies keeps EUR 97.00 target
On September 3, 2026, Jefferies maintained its Buy rating and EUR 97.00 price target, while noting weaker August active-customer and app-use trends. The assessment was published by finanzen.net.
Redcare stock trades above EUR 74
Redcare Pharmacy stock was trading at EUR 74.75 at Lang & Schwarz on September 30, 2026 at 4:08 p.m. CEST, up 4.77 percent versus the Lang & Schwarz prior close of EUR 71.35. The company is scheduled to publish its Q3 2026 interim statement on October 29, 2026, according to FT.com.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC
- Primary exchange: Frankfurt Stock Exchange, Prime Standard
- Price Lang & Schwarz as of September 30, 2026, 4:08 p.m. CEST: EUR 74.75
- Change versus prior close: plus 4.77 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 71.35
- Market capitalization: EUR 1.5 billion (as of September 30, 2026)
- 52-week range: EUR 30.20-90.10 (as of September 30, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
